Twist Bioscience Opens New Twist Boston Location to Expand Antibody Discovery Capacity
July 06 2022 - 7:00AM
Business Wire
New facility increases in vivo antibody
discovery capacity
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the opening of its
new Twist Boston location in Quincy, Massachusetts.
“This is a year of growth for Twist, as we work to bring the
Factory of the Future online in Oregon while expanding our in vivo
antibody discovery capacity through our new Twist Boston location,”
said Emily M. Leproust, Ph.D., CEO and co-founder of Twist
Bioscience. “Twist is one of the first biotech companies to open a
site in Quincy, and we were pleased to find an ideal space that
fits our aggressive growth plans to serve our biopharma partners in
accelerating antibody discovery for a wide range of therapeutic
targets.”
Twist Boston, formerly known as Abveris, was acquired by Twist
Bioscience in November 2021 to add in vivo antibody discovery
expertise to Twist Biopharma’s antibody discovery and optimization
capabilities using robust, precisely written synthetic libraries.
Twist Boston empowers the development of the next generation of
biologics, cell therapies, vaccines, and diagnostics by using its
DiversimAb™ family of hyperimmune mouse models to complete
discovery and characterization services for global biopharma
leaders. Antibodies discovered using the DiversimAb platform can be
humanized using the Twist antibody optimization (TAO) platform to
develop superior biologics for rapid clinical advancement. The new
Twist Boston location boasts state-of-the-art antibody discovery
workflow tools, including a total of four Berkeley Lights Beacon®
Optofluidic Platforms, for increased screening capacity for
discovery projects necessitating ultra-rapid high-content function
forward screening. Twist has the option to expand the size of the
site to accommodate future growth.
About Twist Boston
Twist Boston provides premium in vivo antibody discovery
services to the biopharma industry. The company applies advanced
immunization methods combined with B cell screening and
hybridoma-based antibody discovery technologies to provide
comprehensive gene-to-antibody discovery services. Twist Boston is
developing the next generation of biologics, cell therapies,
vaccines, and diagnostics in partnership with global biopharma
leaders. Additional information about Twist Boston, also known as
Abveris, is available at www.abveris.com.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on May 6,
2022 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220706005295/en/
For Twist Bioscience: Angela Bitting SVP, Corporate
Affairs 925- 202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024